Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

CASE REPORT
[View FULLTEXT] [Download PDF
 
Year : 2022  |  Volume : 68  |  Issue : 1  |  Page : 38-40  

Unusual severe gastritis and gastric ulcers caused by pembrolizumab

WT Liu1, YF Li2, TY Hsieh3 
1 Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
2 Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
3 Department of Division of Gastroenterology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Correspondence Address:

Pembrolizumab (an immune checkpoint inhibitor)-related gastritis and gastric ulcers are rare immune-related adverse events, which are insufficiently treated with proton pump inhibitors (PPIs) therapy alone, and usually require systemic steroid therapy and even other biological agents (such as infliximab) in severe cases. Here, we report a case of 49-years-old woman suffering from gastritis and gastric ulcers after pembrolizumab treatment, which was refractory to 2 months of PPI therapy. The diagnosis was made by the clinical and histopathologic presentations. She had immediate resolution of abdominal symptoms after initiation of steroid treatment, but the gastritis and gastric ulcers improved slowly and lasted for months as shown in endoscopy. She was finally treated with extended steroid therapy without serious complications. We discuss the latest treatment options and our management strategies of the case.


How to cite this article:
Liu W T, Li Y F, Hsieh T Y. Unusual severe gastritis and gastric ulcers caused by pembrolizumab.J Postgrad Med 2022;68:38-40


How to cite this URL:
Liu W T, Li Y F, Hsieh T Y. Unusual severe gastritis and gastric ulcers caused by pembrolizumab. J Postgrad Med [serial online] 2022 [cited 2022 Dec 1 ];68:38-40
Available from: https://www.jpgmonline.com/article.asp?issn=0022-3859;year=2022;volume=68;issue=1;spage=38;epage=40;aulast=Liu;type=0


 
Thursday, December 1, 2022
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer